Multiple Sclerosis (MS) is a complex autoimmune disease caused by a combination of genetic and environmental factors. Translation of Genome-Wide Association Study (GWAS) findings in MS into therapeutics and effective preventive strategies has been limited to date.
Introduction
Genome-wide association studies (GWAS) in Multiple Sclerosis (MS) have revealed over 200 risk loci associated with an increased risk of developing the disease 1 . However, translating findings from GWAS into therapeutic strategies has proved challenging for a number of reasons. GWAS provide insights into potential genomic risk loci that are likely to harbour single or multiple causal variants. Despite the advent of analytical techniques such as fine-mapping, advanced annotation tools, colocalisation, and mendelian randomisation for inferring causal variants from risk loci, difficulties remain in inferring with certainty which variants are truly causal. Understanding how these variants mechanistically influence disease phenotypes provides additional challenges 2 . These challenges arise from factors such as complex linkage disequilibrium and potential effects on distant (i.e. trans) genes.
Additionally, dynamic, context-specific effect of variants are likely to vary depending on time, cell type, and context.
MS is a complex autoimmune disease, which is a leading cause of disability in young people.
There are currently neither effective cures nor preventive measures for MS. Licensed therapies for MS include rationally-designed monoclonal antibodies, such as ocrelizumab and ofatumumab (anti-CD20), natalizumab (anti-alpha4 integrin) and alemtuzumab (anti-CD52), and fingolimod (sphingosine-1-phosphate-receptor modulators), in addition to drugs with multiple mechanisms of action such as cladribine, glatiramer acetate, and beta-interferon 3 .
Autologous haematopoietic stem cell transplant (aHSCT) has in increasing evidence base for use in MS. Existing highly-active therapies are effective at controlling inflammatory disease activity, but have several serious side-effects; alongside this, prognostication at the time of diagnosis remains imperfect. There is thus an unmet clinical need for highly-effective therapies with a better safety profile, which is even more important when considering preventive drugs for individuals at high-risk of disease.
Many GWAS hits reside in intronic or intergenic regions, or within genes that do not make attractive druggable targets, for example due to conformational considerations, cellular localisation, or concerns about off-target effects. Outside of rare, missense or nonsense coding variants, moving from GWAS hits into druggable targets has had limited success.
Expression Quantitative Trait Loci (eQTL) studies provide a tissue-specific measure of genetic expression and enable a deeper understanding of the influence of transcription levels alongside genetic variation. Summary-data based mendelian randomization (SMR) provides a data-driven approach for integrating GWAS data with gene expression data from expression quantitative trait locus (eQTL) studies to prioritise potentially causal genes from GWAS hits 4 . SMR extends the concept of mendelian randomisation, enabling testing of the hypothesis that genetically-determined levels of gene expression are associated with a disease phenotype.
In this paper, we focus on a previously curated list of 4479 genes that were identified as 'druggable' on the basis of various considerations 5 . We apply SMR to recent MS GWAS data, complemented by pathway analysis to provide a data-driven prioritisation of druggable genes in MS.
Methods

Datasets
MS GWAS data were provided by the International MS Genetics Consortium (IMSGC) from the latest IMSGC discovery-stage summary statistics 1 . These data originate from 14, 802 individuals with MS and 26,703 controls of European descent. Allele frequencies for SNPs in the MS GWAS discovery data were obtained from the 1000 genomes samples of European ancestry (n=503) 6 .
For SMR analyses, we used several expression Quantitative Trait Loci (eQTL) datasets. The primary analysis used cis-eQTL data from the eQTLgen consortium. This dataset contains cis-eQTLs for all 19,250 genes expressed in whole blood obtained from 31,684 individuals.
Each SNP-gene pair for which data was available in ≥ 2 cohorts and with a SNP-gene distance of ≤ 1MB was tested 7 . Data were downloaded from the eQTLgen consortium website (https://www.eqtlgen.org/cis-eqtls.html) 7 . Whole blood results obtained with the eQTLgen dataset were replicated using the Consortium for the Architecture of Gene Expression (CAGE) consortium eQTL data obtained from peripheral blood of 2,765 individuals 8 
SMR
Summary-data based mendelian randomisation (SMR) is a technique used to determine associations between genetically-determined traits, such as gene expression and methylation, and outcomes of interest, such as disease phenotypes 4 . eQTLs refer to genetic variants which are associated with levels of expression of a particular transcript. These are derived from the measurement of gene expression, most commonly using RNA sequencing, which is then correlated with genotyping data. Importantly, eQTLs are time and tissue-specific: the genetic regulation of gene expression varies widely between tissues and depends on context.
In SMR, SNP association statistics with an outcome (e.g. a disease phenotype) are regressed on SNP association statistics with expression of a particular transcript to determine a 'causal estimate', approximating the effect on the disease phenotype for a genetically-determined increase in the expression of that transcript. If ߚ E is the per-allele beta for a geneticallydetermined increase in gene expression, and ߚ D is the per-allele log odds ratio for a binary disease phenotype, then the causal estimate for the effect of genetically-determined increased expression of that transcript
A key assumption of this approach is that the same underlying causal variant determines both gene expression and the disease phenotype.
Due to linkage disequilibrium, it is possible that ߚ SMR could be non-zero even when this assumption is violated, i.e if SNP i is in linkage with SNP j , which determines the expression of transcript t , and is also in linkage with SNP k, which directly influences the disease phenotype, then ߚ SMR may be non-zero despite no direct causal pathway from SNP to transcript to disease (see figure 1 in Wu et al 2 ). This is different to the 'vertical pleiotropy' situation upon which instrumental variable analysis and MR are based, which assumes a direct causal pathway between genetic variant, gene expression, and disease phenotype. hg19 6:25,000,000 -35,000,000) given the complex LD structures within this region. LD estimation was performed using reference genomes obtained from the 1000 genomes samples of European ancestry (n=503) 6 .
Multi-omic SMR
To further refine the list of plausible druggable targets developed using the techniques above, we performed multi-omic SMR using the methods described in Wu et al 2 . This approach prioritises genes by layering SNP associations with CpG methylation sites, gene expression, and the phenotype of interest. As the majority of GWAS hits are in non-coding regions, they are likely to influence disease through regulation of gene expression 2 . As CpG methylation sites are partly genetically-determined, methylome-wide association study (MWAS) data can be exploited to determine likely causal relationships between CpG methylation and other traits, including molecular traits such as gene expression. We applied the following steps to prioritise druggable genes in MS: Custom gene tracks for locus plots were downloaded from the USCS Genome Browser (https://genome.ucsc.edu/cgi-bin/hgTables). All genomic co-ordinates specified are genome build hg19 (GRCh37).
Pathway analysis, functional annotation, and prediction of protein interactors
Pathway analysis and annotation was conducted using the STRING database of proteinprotein interactions (https://string-db.org/). For data visualisation, we used default settings to map protein-protein interactions between the prioritised druggable targets. STRING database interaction scores are curated from multiple sources (experimental data, co-expression, textmining, and predictions from peptide sequences) and reflect the probability that two proteins are linked in the same KEGG metabolic pathway. By default, interactions with medium confidence (>0.4) are shown 11, 12 . For functional enrichment analysis, we examined the list of SMR-prioritised genes (not restricted to the druggable genome).
Enrichment for Gene Ontology (GO) terms and biological pathways was determined by querying GO terms, KEGG pathways, and REACTOME pathways using STRING 13 .
Enrichment P values are computed using hypergeometric tests and corrected using the Benjamini-Hochberg procedure. The hypergeometric test for enrichment is based on the observation that under the null hypothesis (no enrichment), the number of genes from the gene list which have a particular GO term attached follows an approximately binomial distribution for large n values 14 .
To identify additional druggable targets not prioritised in the primary analysis but likely to interact with prioritised genes, we used the GeNets tool (http://apps.broadinstitute.org/genets). GeNets uses pre-trained random forest classifiers to predict the likelihood that any given protein interacts functionally with another. In addition to calculating interaction strength between given gene products, GeNets can also predict likely interacting partners given a gene set. We ran GeNets using the online tool, with the SMRprioritised gene list from our primary analysis (eQTLgen SMR, supplementary Mellitus, Sjogren's Syndrome, and Primary Sclerosing Cholangitis) and haematological malignancies. These diseases areas were chosen given their potentially shared aetiology with MS; successful trials in these diseases may suggest possible therapeutic benefit in MS.
Statistical analysis, software, and computing
All analyses were conducted using SMR and R v3.6.1. This research was supported by the High-Performance Cluster computing network hosted by Queen Mary University of London 16 . SMR locus plots were made using the online tool hosted at the SMR website (https://cnsgenomics.com/software/smr/omicsplot/).
Results
Expression of druggable gene targets is modulated by MS risk loci
We used SMR to test the association of genetically-determined expression of druggable genes in peripheral blood with multiple sclerosis. Expression of 45 tested probes (mapping to 45
unique genes; 2356 probes tested in total) was associated with MS (FDR SMR 0.05, p HEIDI > 0.01, figure 1). Twenty of these genes were Tier 1 druggable targets (figure 1, figure 2, table   1 ). 17 of these 45 signals were replicated in the CAGE dataset (supplementary tables 1 & 2, supplementary figure 1). For these replicated genes, the association statistics (beta SMR ) with MS were highly correlated between the two datasets (Pearson's correlation coefficient 0.93, 95% CI 0.83 -0.98, p = 4.20x10 -8 , supplementary tables 1 & 2, supplementary figure 2).
We found evidence for multiple protein-protein interactions within this list of prioritised druggable genes (figure 3a). Extending the SMR approach beyond the druggable genome, expression of 235 genes was associated with MS risk (FDR SMR < 0.05, p HEIDI >0.01, supplementary table 3, figure 3b ). This full set of SMR-prioritised genes was enriched for multiple GO terms and biological pathways implicated in immune system function and dysfunction (supplementary table 4 -6) . No significant enrichment was found for REACTOME pathways nor for GO cellular components.
Methylation at CpG sites is modulated by MS risk loci
Next, in order to determine CpG methylation sites associated with MS risk, we applied SMR to CpG mQTL data from a meta-analysis of the LBC and BSGS cohorts (see methods). We found evidence for an association of 574 CpG methylation probes with MS risk (table 2) .
Multi-omic SMR to prioritise druggable gene candidates in MS
To determine the associations between CpG methylation sites and gene expression, we performed SMR using the LBC and BSGS mQTL meta-analysis and the eQTLgen consortium eQTL data. We restricted this analysis to druggable gene transcripts and excluded the MHC. We identified 23,731 associated pairs of CpG probes and transcripts (FDR SMR < 0.05, p HEIDI > 0.01) mapping to 2548 unique genes (supplementary table 7 ).
We then overlaid SMR evidence for causal relationships between methylation and expression 
Prediction of novel interactions
To extend the list of functionally-prioritised druggable targets, we used GeNets to predict which proteins interact with the targets identified in our analysis. As input, we used the full list of 235 SMR-prioritised genes (including non-druggable targets) from the primary analysis (supplementary table 3 ). This approach yielded an additional 75 predicted protein interaction partners and multiple novel and established therapeutic compounds targeting our list of prioritised protein networks (supplementary figure 4, supplementary table 10).
Druggable targets in lymphoblastoid cell lines (LCLs)
EBV-transformed cell lines, Lymphoblastoid Cell Lines (LCLs), provide a model for studying gene expression on B cells in vitro. These cells are immortalised using EBV, which apppears to play a significant role in MS risk. We attempted to identify druggable gene targets in LCLs using LCL-eQTL data from the Geuvadis consortium 9 . SMR identified 7
prioritised druggable gene targets for MS in LCLs (supplementary table 10, supplementary figure 5). Expression of 3/7 of these transcripts (SLC12A7, FCRL3, and SLAMF7) was also associated with MS susceptibility in blood, with concordant directions of effects for all three genes. The FCRL3 gene was the only gene that overlapped with our list of genes prioritised using multi-omic SMR, although notably the TNFRSF14 gene prioritised from the LCL analysis is adjacent to MMEL1, which was nominated by the multi-omic method as a likely causal gene in peripheral blood. Comparison of SMR causal estimates for gene expression of the 1215 overlapping genes which passed the HEIDI test (p > 0.01) revealed a weak but precisely estimated positive correlation between association statistics with MS in blood and LCLs (Pearson's rho = 0.27, 95% CI 0.21 -0.32, p<2x10 -16 ).
Systematic review of clinical trials
We conducted a systematic review of clinical trials targeting our twenty Tier 1 prioritised genes from the primary analysis (eQTL SMR with eQTLgen data 
Discussion
In this report we combine the latest IMSGC GWAS data with large mQTL and eQTL datasets and a list of curated 'druggable genes' to provide a data-driven list of 45 prioritised drug targets for multiple sclerosis. Three of these targets -CD40, MERTK, and PARP1 -have strong evidence to support a biological causal relationship between genetic variation, 25, 26 , an effect which is replicated in our study (Beta SMR -0.50, p SMR = 1.89x10 -12 ). In a study of PBMCs from people with MS and healthy controls, the susceptibility SNP rs4810485 was associated with both alternative splicing of CD40 transcripts -with relative upregulation of the splice isoform lacking exon 5 leading to lower cell-surface expressionand with lower levels of the anti-inflammatory cytokine IL-10 in peripheral blood 26 . These data suggest that genetically-determined modulation of CD40 mRNA expression may promote MS risk via effects of alternatively-spliced transcripts on IL-10 production, although the exact mechanism remains to be clarified. Monoclonal antibodies blocking the interaction between CD40L and CD40 have shown efficacy in rodent and primate EAE 24 .
Drug trials of anti-CD40 therapies in humans have been limited by safety concerns. Early phase II data showed promising efficacy of an anti-CD40L mAb in lupus nephritis 27 . Despite phase I safety of the anti-CD40L antibody, IDEC-131, in MS, the phase II trial was halted due to increased risk of thromboembolic disease caused by inhibition of the thrombusstabilising interaction between CD40L and platelet alpha2,beta3 integrins 24, 28 . Subsequently, various strategies have been deployed to overcome this safety concern. The thrombogenicity of CD40L antagonists is dependent on an Fc-FcγRIIa interaction leading to platelet crosslinking 29 ; development of a PEGylated monovalent anti-CD40L Fab fragment lacking an Fc portion appears to have overcome this problem 30 . A placebo-controlled phase II trial of dapirolizumab pegol for individuals with SLE has been completed (results pending; NCT 02804763). An anti-CD40L antibody-like molecule based on a Tn3 protein scaffold has shown phase I safety and preliminary efficacy in individuals with rheumatoid arthritis 31 .
In addition to directly targeting the CD40L-CD40 interaction, it may be beneficial to target and may be involved in B cell differentiation and activation 43 . There is some evidence linking increased PARP1 activity to autoimmunity. Specific PARP1 haplotypes are associated with RA 44 . Some, but not all, EAE studies have demonstrated efficacy of PARP1 inhibitors in limiting disease severity 43 . In our study, surprisingly, the direction of SMR effect implies that increased PARP1 expression is protective against MS (Beta SMR -0.31, 2.95x10 -195 ).
Data-driven efforts to prioritise drug targets in MS using SMR have been limited to date. One study used older GWAS data and smaller eQTL datasets (Westra et al and CAGE) to prioritise 10 non-MHC genes and 20 non-MHC methylation loci associated with MS in peripheral blood 45 . Our use of larger, more recent datasets, a more lenient HEIDI threshold, and an FDR cutoff rather than a Bonferroni correction is likely to explain our discovery of a greater number of genes. To our knowledge, ours is the first attempt to synthesise SMR with a curated list of druggable targets to prioritise genes for therapy in MS.
An important limitation is that our analyses focus on whole blood, partly because this is the tissue for which the largest eQTL and mQTL datasets exist. As the genetic determinants of gene expression vary between tissues, this paper focuses on identifying differentially- A further limitation of our work is that SMR identifies genes in which the level of expression is associated with disease. There are many ways whereby gene and protein function may influence phenotype independently of levels of gene expression, such as through changes in subcellular localisation and post-translational modifications. In addition, the effect of expression of a single gene is likely to depend on the overall transcriptional and translational state of the cell at that point; this complexity is not captured by considering the expression of individual genes separately. Furthermore, the curated list of druggable genes does not imply that a gene is necessarily a sensible target; some prioritised genes with multiple roles in cell signalling, such as CD40, may be challenging to target in practice without unacceptable offtarget effects.
In summary, using data-driven mendelian randomisation and publicly-available datasets, we highlight several possible drug targets for multiple sclerosis. In particular, we highlight a central role for the CD40 signalling pathway, which could be targeted with small molecule compounds already being trialled for other indications.cg21601405 0 25 49 74cg01943874 0 11 22 33cg23712594 0 17 34 51
